Adagene IncNASDAQ:ADAG
- LAST PRICE2.2600
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots2.2600/ 1
- Ask / Lots2.5000/ 1
- Open / Previous Close--- / 2.2600
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ADAG |
|---|---|---|
| 09:32 ET | 351 | 2.1501 |
| 09:39 ET | 200 | 2.19 |
| 10:02 ET | 100 | 2.19 |
| 11:02 ET | 100 | 2.3458 |
| 11:18 ET | 205 | 2.21 |
| 11:48 ET | 250 | 2.3198 |
| 12:19 ET | 300 | 2.3 |
| 12:37 ET | 100 | 2.31 |
| 01:27 ET | 100 | 2.2893 |
| 02:12 ET | 100 | 2.25 |
| 02:14 ET | 100 | 2.28 |
| 02:16 ET | 3755 | 2.3 |
| 02:20 ET | 500 | 2.3005 |
| 02:25 ET | 130 | 2.305 |
| 02:30 ET | 642 | 2.31 |
| 02:34 ET | 5696 | 2.3 |
| 02:36 ET | 350 | 2.34 |
| 02:38 ET | 100 | 2.21 |
| 02:52 ET | 6380 | 2.21 |
| 02:57 ET | 100 | 2.2962 |
| 03:24 ET | 200 | 2.21 |
| 03:33 ET | 200 | 2.34 |
| 03:48 ET | 500 | 2.23 |
| 03:50 ET | 1668 | 2.22 |
| 03:53 ET | 246 | 2.245 |
| 04:00 ET | 200 | 2.26 |
Nov 7, 2024
Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody(R) ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, from 10:01AM ET on Thursday Nov 07, 2024 by Dow Jones
10:01AM ET on Thursday Nov 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Adagene Inc | 100.1M | -3.1x | --- |
Werewolf Therapeutics Inc | 79.3M | -1.2x | --- |
TriSalus Life Sciences Inc | 129.8M | -2.6x | --- |
Aligos Therapeutics Inc | 71.0M | -1.1x | --- |
Fennec Pharmaceuticals Inc | 129.5M | -47.0x | --- |
Ikena Oncology Inc | 94.5M | -1.4x | --- |
Company Information
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
Contact Information
- Headquarters
- 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial ParkSUZHOU, JNG, China 215123
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer, Co-Founder
- Peter Luo
- Chief Financial Officer, Director
- Tam Man Kin
- Executive Vice President of Clinical Development
- Zha Jiping
- Senior Vice President of Global Regulatory Affairs
- Shang Jin
- Senior Vice President, Head of Clinical Operations
- She Xiaohong
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $100.1M |
|---|---|
Revenue (TTM) | $815.8K |
Shares Outstanding | 44.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.52 |
EPS | $-0.72 |
Book Value | $1.60 |
P/E Ratio | -3.1x |
Price/Sales (TTM) | 122.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -4,534.81% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
